The Cytokine Storm and COVID-19

Overview

Journal J Med Virol

Specialty Microbiology

Date 2020 Jun 28

PMID 32592501

Citations 767

Authors

Biying Hu

Shaoying Huang

Lianghong Yin

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19), which began in Wuhan, China, in December 2019, has caused a large global pandemic and poses a serious threat to public health. More than 4 million cases of COVID-19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been confirmed as of 11 May 2020. SARS-CoV-2 is a highly pathogenic and transmissible coronavirus that primarily spreads through respiratory droplets and close contact. A growing body of clinical data suggests that a cytokine storm is associated with COVID-19 severity and is also a crucial cause of death from COVID-19. In the absence of antivirals and vaccines for COVID-19, there is an urgent need to understand the cytokine storm in COVID-19. Here, we have reviewed the current understanding of the features of SARS-CoV-2 and the pathological features, pathophysiological mechanisms, and treatments of the cytokine storm induced by COVID-19. In addition, we suggest that the identification and treatment of the cytokine storm are important components for rescuing patients with severe COVID-19.

Citing Articles

Advances in treatment strategies for COVID-19: Insights from other coronavirus diseases and prospects.

Li Y, Lan J, Wong G Biosaf Health. 2025; 5(5):272-279.

PMID: 40078910 PMC: 11895002. DOI: 10.1016/j.bsheal.2023.08.003.

The influence of genetic polymorphisms on cytokine profiles in pediatric COVID-19: a pilot study.

Kozak K, Pavlyshyn H, Kamyshnyi O, Shevchuk O, Korda M, Vari S Front Pediatr. 2025; 13:1523627.

PMID: 40066463 PMC: 11891370. DOI: 10.3389/fped.2025.1523627.

High nasopharyngeal and serum IL-6 levels and the - 573G > C polymorphism (rs1800796) are linked with the risk of severe COVID-19 in a Mexican population: a case‒control study.

Torres-Poveda K, Bahena-Roman M, Contreras-Ochoa C, Lagunas-Martinez A, Bermudez-Morales V, Pando-Robles V BMC Infect Dis. 2025; 25(1):315.

PMID: 40045221 PMC: 11884130. DOI: 10.1186/s12879-025-10695-y.

Complement is primarily activated in the lung in a mouse model of severe COVID-19.

Szachowicz P, Wohlford-Lenane C, Donelson C, Ghimire S, Thurman A, Xue B iScience. 2025; 28(3):111930.

PMID: 40034849 PMC: 11875145. DOI: 10.1016/j.isci.2025.111930.

Should the Start of Immunosuppressive Treatment for COVID-19 Rely upon the Degree of Inflammation or the Time from Onset?.

Mora-Lujan J, Montero A, Formiga F, Rubio-Rivas M Medicina (Kaunas). 2025; 61(2).

PMID: 40005350 PMC: 11857332. DOI: 10.3390/medicina61020233.

References

Teijaro J, Walsh K, Rice S, Rosen H, Oldstone M . Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A. 2014; 111(10):3799-804. PMC: 3956176. DOI: 10.1073/pnas.1400593111. View

Forster P, Forster L, Renfrew C, Forster M . Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020; 117(17):9241-9243. PMC: 7196762. DOI: 10.1073/pnas.2004999117. View

Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q . Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020; 11(2):216-228. PMC: 7069465. DOI: 10.14336/AD.2020.0228. View

Hussman J . Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. Front Pharmacol. 2020; 11:1169. PMC: 7406916. DOI: 10.3389/fphar.2020.01169. View

Russell C, Millar J, Baillie J . Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473-475. PMC: 7134694. DOI: 10.1016/S0140-6736(20)30317-2. View

Wong C, Lam C, Wu A, Ip W, Lee N, Chan I . Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1):95-103. PMC: 1808997. DOI: 10.1111/j.1365-2249.2004.02415.x. View

Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X . Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing). 2020; 6(10):1153-1161. PMC: 7102606. DOI: 10.1016/j.eng.2020.02.006. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

10.

Al-Bari M . Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015; 70(6):1608-21. PMC: 7537707. DOI: 10.1093/jac/dkv018. View

11.

Bogoch I, Watts A, Thomas-Bachli A, Huber C, Kraemer M, Khan K . Potential for global spread of a novel coronavirus from China. J Travel Med. 2020; 27(2). PMC: 7074660. DOI: 10.1093/jtm/taaa011. View

12.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

13.

Li H, Liu L, Zhang D, Xu J, Dai H, Tang N . SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020; 395(10235):1517-1520. PMC: 7164875. DOI: 10.1016/S0140-6736(20)30920-X. View

14.

Huang K, Su I, Theron M, Wu Y, Lai S, Liu C . An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2004; 75(2):185-94. PMC: 7166886. DOI: 10.1002/jmv.20255. View

15.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

16.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

17.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

18.

Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-OCallaghan A, Pardos-Gea J, Quintana A . Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020; 19(7):102569. PMC: 7252146. DOI: 10.1016/j.autrev.2020.102569. View

19.

Yao X, He Z, Li T, Zhang H, Wang Y, Mou H . Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020; 30(6):541-543. PMC: 7186763. DOI: 10.1038/s41422-020-0318-5. View

20.

Valk S, Piechotta V, Chai K, Doree C, Monsef I, Wood E . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020; 5:CD013600. PMC: 7271896. DOI: 10.1002/14651858.CD013600. View